FULLERTON, CA – MARCH 15, 2011 – The European Union has recently approved for commercialization the Calamarine line of responsibly sourced, high docosahexaenoic acid (DHA) Omega-3 ingredients. Derived from the byproducts of food-grade calamari (Cephalopoda), Calamarine Omega-3 oils offer a high quality alternative to potentially overexploited fish species often used in the manufacture of high DHA Omega-3 products.
On behalf of the European Food Safety Authority, the General Chemical State Laboratory in Athens, Greece has determined that Calamarine ingredients are the substantial equivalent of tuna-derived omega-3. Further, the investigators found that heavy metals, pesticides, dioxins, and other toxins in Calamarine were well within safe levels as established by European Union Commission Regulations.
Commenting on the European Union decision, company R&D Director and Omega-3 industry veteran Asgeir Saebo stated, “We are very pleased that the European Food Safety Authority, after evaluating the scientific literature, toxicology analysis, and data on the fatty acid profile, has unanimously approved Calamarine for EU market entry. I expect that the health benefits from high DHA Calamarine oil will be superior to the typical marine-derived EPA omega-3 products. After all, DHA accounts for more than 90% of the omega-3 in the human eyes and brain and more than 70% of the omega-3 in blood and heart tissue.”
About Pharma Marine Group
Pharma Marine is located on the west coast of Norway, near Aalesund, a region where refining marine oils dates back more than 150 years. In addition to advanced purification technologies that create exceptional taste and smell dynamics, the facility is a model for “green” manufacturing procedures that dramatically reduce environmental impact and carbon footprint. Pharma Marine Group is the only supplier of Calamari-derived Omega-3 concentrates. For more information, please visit our website http://www.pharmamarine.com
Location: Fullerton, CA
Contacts: Todd Parker (North America); Leif Kjetil Gjendemsjo (Rest of World)
Phone: +1 (714)-871-1998 (North America); +47 92609960 (Rest of World)
E-Mail: todd@pharmamarine.com (North America); leif@pharmamarine.no (Rest of World)
Web Address: http://www.pharmamarine.com
